ClinicalTrials.gg
CompletedNCT02568176Updated Feb 3, 2025

Pharmacokinetic Study of Intranasal Esketamine and Its Effects on the Pharmacokinetics of Orally-Administered Midazolam and Bupropion in Healthy Participants

A Phase 1 interventional study of Midazolam and Esketamine in Healthy, sponsored by Janssen Research & Development, LLC. Completed at 1 site in Belgium. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-02-03.

Sponsored by Janssen Research & Development, LLC (part of Johnson & Johnson) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
71
Allocation
Non-randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

The primary purpose of this study is to evaluate the induction potential of repeated administration of intranasal esketamine on cytochrome P450 (CYP) 3A4 and CYP2B6 activity in healthy participants using orally administered midazolam and bupropion as probes, respectively and to evaluate the pharmacokinetics of esketamine after a single dose and repeated administration.

Read the detailed description

This is a parallel group, single-center, repeat-dose, fixed-sequence, open-label (all people know the identity of the intervention), study. The effects of repeated administration of intranasal esketamine on the pharmacokinetics of midazolam and bupropion will be evaluated in Cohort 1 and Cohort 2, respectively. Participants in Cohort 1 will receive a single oral dose of midazolam in the morning of Day 1 and Day 17. Participants in Cohort 2 will receive a single oral dose of bupropion in the morning of Day 1 and Day 19. In Cohort 1 and 2 participants will self-administer 5 doses of intranasal esketamine over a 15-day period. The duration of study, from the Screening Phase through Follow-up, is up to 51 days and 54 days for Cohort 1 and Cohort 2, respectively. Blood samples for participants in Cohort 1 will be collected for up to 24 hours after dosing on Days 1 and 17 (midazolam) and for up to 24 hours on Days 2 and 16 (esketamine); For participants in Cohort 2, blood and urine samples for assessment of bupropion pharmacokinetics will be collected for up to 72 hours after dosing on Day 1 and Day 19. Participants' safety will be monitored throughout the study.

02

Conditions studied

  • Healthy

Keywords

  • Healthy
  • Pharmacokinetics
  • Esketamine
  • JNJ-54135419
  • Midazolam
  • Bupropion
03

In context

Lead sponsor

Janssen Research & Development, LLC is the lead sponsor of 932 studies on the registry; 76 are open to participants now.

Of its 285 completed or terminated interventional studies of FDA-regulated products, 137 (48%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Be a man or woman of non-Asian origin 18 to 55 years of age, inclusive
  • Signed an document indicating they understand the purpose of and procedures required for the study and are willing to participate in the study
  • A woman of , must have a negative serum β-human chorionic gonadotropin (hCG) pregnancy test at Screening and a negative urine pregnancy test on Day -1 of the treatment period. Women using must agree to use an additional birth control method during the study and for 1 month after receiving the last dose of study drug
  • A man who is sexually active with a woman of childbearing potential and has not had a vasectomy, must agree to use an adequate contraception method as deemed appropriate by the investigator (eg, vasectomy, double-barrier, partner using effective contraception) and to not donate sperm during the study and for 3 months after receiving the last dose of study drug
  • Comfortable with self-administration of intranasal medication and able to follow instructions provided

Exclusion criteria

Exclusion Criteria:

  • abnormal values for hematology, clinical chemistry (particularly potassium or magnesium levels below the normal laboratory range), or urinalysis at Screening or at admission to the study center (Day -1) as deemed appropriate by the investigator
  • Clinically significant abnormal physical examination, vital signs, or 12 lead (ECG) at Screening or at admission to the study center (Day -1) as deemed appropriate by the investigator
  • Use of any prescription or non-prescription medication (including vitamins and herbal supplements), except for paracetamol, , and hormonal replacement therapy, within 14 days before the first dose of the study drug is scheduled until completion of the study
  • Has used nasal tobacco powder ("snuff") regularly within the past year.
  • Has a nasal piercing
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
71 participants (actual)

Study arms

  • Experimental
    Cohort 1

    Participants will receive single oral dose of midazolam 6 milligram (mg) on Day 1 and 17. Participants will self-administer esketamine intranasally thrice per day on morning of Day 2, 5, 9, 12 and 16 (84 mg).

    Drug: Midazolam · Drug: Esketamine

  • Experimental
    Cohort 2

    Participants will receive single oral dose of bupropion 150 mg on Day 1 and 19. Participants will self-administer esketamine intranasally thrice per day on morning of Day 4, 7, 11, 14 and 18 (84 mg).

    Drug: Esketamine · Drug: Bupropion

Interventions

  • Single oral dose of midazolam 6 mg Day 1 and Day 17.

  • Intranasal esketamine will be self-administered 5 times during 15 days.

    Also known as: JNJ-54135419

  • Single oral dose of bupropion 150 mg on Day 1 and 19.

06

What researchers measure

Primary outcomes

  1. Maximum Plasma Concentration (Cmax)

    The Cmax is the maximum plasma concentration.

    Time frame: up to Day 17 for Cohort 1; up to Day 19 for Cohort 2

  2. Time to reach maximum concentration (tmax)

    Time to reach the maximum observed plasma concentration.

    Time frame: up to Day 17 for Cohort 1; up to Day 19 for Cohort 2

  3. Area Under the Plasma Concentration-Time Curve From Time Zero to Infinite Time (AUC [0-infinity])

    The AUC (0-infinity) is the area under the plasma concentration-time curve from time zero to infinite time, calculated as the sum of AUC(last) and C(last)/lambda(z), wherein AUC(last) is area under the plasma concentration-time curve from time zero to last quantifiable time; and C(last) is the last observed quantifiable concentration; and lambda(z) is elimination rate constant.

    Time frame: up to Day 17 for Cohort 1; up to Day 19 for Cohort 2

  4. Area Under the Plasma Concentration-Time Curve From Time Zero to Infinite Time (AUC [0-last])

    The AUC (0-last) is the area under the plasma concentration-time curve from time zero to last quantifiable time, calculated as the sum of AUC(last) and C(last)/lambda(z), wherein AUC(last) is area under the plasma concentration-time curve from time zero to last quantifiable time; and C(last) is the last observed quantifiable concentration; and lambda(z) is elimination rate constant.

    Time frame: up to Day 17 for Cohort 1; up to Day 19 for Cohort 2

  5. Terminal Half-Life(t[1/2])

    Terminal half-life (t\[(1/2\]) is defined as 0.693/Lambda(z).

    Time frame: up to Day 17 for Cohort 1; up to Day 19 for Cohort 2

  6. Area Under the Plasma Concentration-Time Curve From Time Zero to 12 hours (AUC [0-12])

    The AUC (0-12) is the area under the plasma concentration-time curve from time zero to 12 hours, calculated as the sum of AUC(last) and C(last)/lambda(z), wherein AUC(last) is area under the plasma concentration-time curve from time zero to last quantifiable time; and C(last) is the last observed quantifiable concentration; and lambda(z) is elimination rate constant.

    Time frame: up to Day 17 for Cohort 1; up to Day 19 for Cohort 2

  7. Cmax metabolite to parent ratio (MPR Cmax)

    Cmax metabolite to parent ratio, and corrected for molecular weight if necessary.

    Time frame: up to Day 17 for Cohort 1; up to Day 19 for Cohort 2

  8. AUC(last) metabolite to parent ratio (MPR AUC[last])

    AUC(last) metabolite to parent ratio, and corrected for molecular weight if necessary.

    Time frame: up to Day 17 for Cohort 1; up to Day 19 for Cohort 2

  9. AUC (infinity) metabolite to parent ratio (MPR AUC [infinity])

    AUC (infinity) metabolite to parent ratio, and corrected for molecular weight if necessary.

    Time frame: up to Day 17 for Cohort 1; up to Day 19 for Cohort 2

  10. Amount of Drug excreted in Urine (Ae)

    Total amount excreted into the urine, calculated as the sum of all Ae(t1-t2) intervals.

    Time frame: up to Day 17 for Cohort 1; up to Day 19 for Cohort 2

  11. Percentage of Drug dose excreted into urine

    Total amount excreted into the urine, expressed as a percentage of the administered dose, calculated as (Ae/dose)\*100, and corrected for molecular weight if necessary.

    Time frame: up to Day 19 for Cohort 2

  12. Renal clearance

    Renal clearance calculated as Ae/AUC (infinity).

    Time frame: up to Day 19 for Cohort 2

  13. Formation Clearance

    Formation clearance of drug, calculated as Ae of hydroxybupropion/AUC(infinity) of bupropion, and corrected for molecular weight if necessary.

    Time frame: up to Day 19 for Cohort 2

  14. Ae metabolite to parent ratio (MPR Ae)

    Ae metabolite to parent ratio, and corrected for molecular weight if necessary.

    Time frame: up to Day 19 for Cohort 2

Secondary outcomes

  1. Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)

    An AE was any untoward medical event that occurs in a participant administered an investigational product, and it does not necessarily indicate only events with clear causal relationship with the relevant investigational product. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged in-patient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly.

    Time frame: Baseline up to Day 51 for Cohort 1; Baseline up to Day 54 Cohort 2

07

Study locations

1 site
  • Merksem, Belgium
08

References and documents

Publications

  • Perez-Ruixo C, Rossenu S, Zannikos P, Nandy P, Singh J, Drevets WC, Perez-Ruixo JJ. Population Pharmacokinetics of Esketamine Nasal Spray and its Metabolite Noresketamine in Healthy Subjects and Patients with Treatment-Resistant Depression. Clin Pharmacokinet. 2021 Apr;60(4):501-516. doi: 10.1007/s40262-020-00953-4. Epub 2020 Oct 31. PubMed 33128208 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2015, a primary completion of Feb 2016 and a completion of Feb 2016. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 2, 2015
First posted
Oct 5, 2015
Start
Oct 2015
Primary completionActual
Feb 2016
CompletionActual
Feb 2016
Last update
Feb 3, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 3, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02568176
Responsible party
Sponsor
First posted
Oct 5, 2015
Start date
Oct 2015
Primary completion
Feb 2016
Completion
Feb 2016
Last update
Feb 3, 2025

Study contacts

Janssen Research & Development, LLC Clinical Trial
study director · Janssen Research & Development, LLC

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Midazolam · Bupropion

Start the discussion